Concepedia

E. de Azambuja

ED

Statistics

Publications

2

Citations

47

H-Index

2

Active since

2022

Affiliations

Peter MacCallum Cancer Centre(Current)

Institut Jules Bordet

Gilead Sciences (United States)

Dana-Farber Cancer Institute

E. de Azambuja is an author at Peter MacCallum Cancer Centre specializing in metastatic breast cancer treatment, oncology, and programmed death-ligand 1 inhibitors.

Publications per year

2022–2026

2

Publications

2

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Sara M Tolaney, E. de Azambuja, Kevin Kalinsky et al. · New England Journal of Medicine · 2026 · 29 citations

, , +17

276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

S.M. Tolaney, E. de Azambuja, L.A. Emens et al. · Annals of Oncology · 2022 · 18 citations · Full text

, , +16

1–2 of 2